Article
Urology & Nephrology
Brad H. Rovin, Richard Furie, Y. K. Onno Teng, Gabriel Contreras, Ana Malvar, Xueqing Yu, Beulah Ji, Yulia Green, Tania Gonzalez-Rivera, Damon Bass, Jennifer Gilbride, Chun-Hang Tang, David A. Roth
Summary: Belimumab was found to be most effective in improving kidney response in patients with proliferative lupus nephritis and baseline urine protein/creatinine ratio under 3 g/g. However, it did not show improvement in kidney response in patients with lupus nephritis and sub-epithelial deposits or with a baseline protein/creatinine ratio of 3 g/g or more.
KIDNEY INTERNATIONAL
(2022)
Article
Urology & Nephrology
Ioannis Parodis, Julius Lindblom, Nursen Cetrez, Leonardo Palazzo, Henri Ala, Frederic A. Houssiau, Christopher Sjoewall, Brad H. Rovin
Summary: In this study, we evaluated the efficacy of belimumab in preventing de novo renal flares and identified factors associated with renal flare occurrence. We found that Asian origin, positive baseline anti-double stranded DNA levels, and increasing mean prednisone dose during follow-up were associated with de novo renal flares.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Medicine, General & Internal
Muhammad Shipa, Andrew Embleton-Thirsk, Mariea Parvaz, Liliana Ribeiro Santos, Patrick Muller, Kashfia Chowdhury, David A. Isenberg, Caroline J. Dore, Caroline Gordon, Michael R. Ehrenstein
Summary: In patients with refractory systemic lupus erythematosus (SLE), the use of belimumab following rituximab significantly reduced serum IgG anti-dsDNA antibody levels and decreased the risk of severe disease flares, suggesting the potential for this combination as a therapeutic strategy.
ANNALS OF INTERNAL MEDICINE
(2021)
Article
Medicine, General & Internal
Aishwarya Gopal, Chengappa Kavadichanda, Devender Bairwa, Sanket Shah, Sonal Mehra, Bheemanathi Hanuman Srinivas, Christina Mary Mariaselvam, Molly Mary Thabah, Vir Singh Negi
Summary: This study evaluated the performance of clinical and biochemical parameters in identifying renal histopathology, as well as the performance of a combination of demographic, clinical, serologic, and histopathological parameters in predicting renal response at one year. The results showed that clinical and biochemical parameters alone have poor specificity in identifying renal histopathology, while a combination of demographic, clinical, and histopathological parameters can better predict renal outcomes at one year.
Review
Urology & Nephrology
Juan M. Mejia-Vilet, Ana Malvar, Arnon Arazi, Brad H. Rovin
Summary: This article discusses the approval of two drugs by the US Food and Drug Administration for the treatment of lupus nephritis (LN), and emphasizes the need to rethink the overall management strategy of LN, including utilizing kidney biopsies for management, applying molecular technologies to interrogate biopsy data, and incorporating LN biomarkers into management paradigms.
KIDNEY INTERNATIONAL
(2022)
Article
Rheumatology
Tao Liu, Rosemarie Neuner, Aliza Thompson, Ginto Pottackal, David Petullo, Jiang Liu, Nikolay Nikolov, Chandrahas Sahajwalla, Suresh Doddapaneni, Jianmeng Chen
Summary: FDA approved Benlysta for the treatment of adult patients with active lupus nephritis, marking the first FDA approved treatment for this condition. The approval of both IV and SC dosing regimens was based on clinical trials and PK modeling. Belimumab demonstrates efficacy in treating patients with LN, with varying responses based on different baseline characteristics.
Review
Medicine, General & Internal
Gabriella Moroni, Marta Calatroni, Beatriz Donato, Claudio Ponticelli
Summary: Despite improvements in renal and obstetrical management, pregnancies in women with glomerular diseases and lupus nephritis are still associated with increased complications. Planning pregnancy during a phase of stable remission and considering a kidney biopsy can help identify and manage potential risks. Kidney biopsies can differentiate between active lesions and chronic irreversible lesions, and may guide appropriate treatment for pregnant women. It is recommended to avoid kidney biopsies after 28 weeks of gestation to minimize the risks.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Urology & Nephrology
Yutian Lei, Jerome Loutan, Hans-Joachim Anders
Summary: Recent studies have found that new drugs like belimumab, obinutuzumab, and voclosporin, used as add-on therapies, may have positive effects in treating lupus nephritis and change the treatment landscape.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
(2021)
Review
Biotechnology & Applied Microbiology
Marlene Pluess, Silvia Piantoni, Bjoern Tampe, Alfred H. J. Kim, Peter Korsten
Summary: Advances in the treatment and management of systemic lupus erythematosus have improved patient outcomes, but lupus nephritis remains a major complication. Belimumab has been shown to be superior as an add-on therapy for lupus nephritis, and personalized treatment options are expected with the development of new therapeutic agents.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Medicine, General & Internal
Filipe Marques, Joana Reis, Iolanda Godinho, Marta Pereira, Paulo Fernandes, Sofia Jorge, Jose Antonio Lopes, Joana Gameiro
Summary: Proteinuria reduction to lower than 1 g/24 h during the first year after diagnosis is a protective factor for the long-term decline of kidney function in patients with glomerular disease, having a more important role than proteinuria or the GFR at the time of the diagnosis.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Emma Weeding, Andrea Fava, Chandra Mohan, Laurence Magder, Daniel Goldman, Michelle Petri
Summary: Objective urine proteomic approaches can identify biological pathways in lupus nephritis, and changes in the urine proteome are associated with treatment response and belimumab therapy.
LUPUS SCIENCE & MEDICINE
(2022)
Review
Immunology
Chengning Zhang, Ming Zeng, Yifei Ge, Kang Liu, Changying Xing, Huijuan Mao
Summary: Belimumab, combined with standard therapy, is an effective and safe treatment option for patients with severe active lupus nephritis, helping to control renal immune inflammation, improve kidney function, and reverse kidney damage.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Urology & Nephrology
Elenjickal Elias John, Athul Thomas, Jeethu Joseph Eapen, Sabina Yusuf, Sanjeet Roy, Anna T. Valson, Vinoi George David, Santosh Varughese, Suceena Alexander
Summary: This study followed up 501 adult patients diagnosed with bacterial infection-related glomerulonephritis over a period of 12 years, showing that parainfectious GN caused predominantly by nonstreptococcal and drug-resistant bacterial infections was associated with poor kidney prognosis.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Urology & Nephrology
Xing-Ji Lian, Li Fan, Xi Xia, Xia-Min Huang, Hong-Jian Ye, Xue-Qing Yu, Hai-Tian Chen, Wei Chen
Summary: The study found that pregnant women with pre-existing LN were at a higher risk of adverse fetal outcomes compared to those with new-onset LN, but both groups had similar adverse maternal outcomes. Serum albumin and proteinuria improved significantly after pregnancy, and the long-term renal outcomes were not significantly different between the two groups.
Article
Urology & Nephrology
Giovanni Maria Rossi, Umberto Maggiore, Francesco Peyronel, Paride Fenaroli, Marco Delsante, Giuseppe Daniele Benigno, Davide Gianfreda, Maria Letizia Urban, Zerai Manna, Lois Johanna Arend, Serena Bagnasco, Augusto Vaglio, Enrico Fiaccadori, Avi Z. Rosenberg, Sarfaraz Hasni, Lucio Manenti
Summary: Early biomarkers play an important role in predicting the risk of end-stage kidney disease (ESKD) or death in proliferative lupus nephritis (LN).
KIDNEY INTERNATIONAL REPORTS
(2022)
Article
Urology & Nephrology
Brad H. Rovin, Richard Furie, Y. K. Onno Teng, Gabriel Contreras, Ana Malvar, Xueqing Yu, Beulah Ji, Yulia Green, Tania Gonzalez-Rivera, Damon Bass, Jennifer Gilbride, Chun-Hang Tang, David A. Roth
Summary: Belimumab was found to be most effective in improving kidney response in patients with proliferative lupus nephritis and baseline urine protein/creatinine ratio under 3 g/g. However, it did not show improvement in kidney response in patients with lupus nephritis and sub-epithelial deposits or with a baseline protein/creatinine ratio of 3 g/g or more.
KIDNEY INTERNATIONAL
(2022)
Article
Rheumatology
Cristina Arriens, Y. K. Onno Teng, Ellen M. Ginzler, Samir V. Parikh, Anca D. Askanase, Amit Saxena, Keisha Gibson, Dawn J. Caster, Tatsuya Atsumi, Laura Lisk, Simrat Randhawa, Rashieda Gluck, Neil Solomons, Robert B. Huizinga
Summary: This integrated analysis evaluates the efficacy and safety of voclosporin in the treatment of lupus nephritis. The study found that voclosporin, in combination with mycophenolate mofetil and oral glucocorticoids, significantly improved renal response compared to control, with similar incidence of adverse events. The results confirm the effectiveness and safety of voclosporin across diverse racial and ethnic groups.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Luuk Wieske, Eileen W. Stalman, P. J. Koos van Dam, Laura Y. Kummer, Maurice Steenhuis, Zoe L. E. van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gertjan Wolbink, Anneke van der Kooi, Joost Raaphorst, Mark Lowenberg, Bart Takkenberg, Geert R. A. M. D'Haens, Phyllis Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederique J. Bemelman, Alexandre Voskuyl, Bo Broens, Agner Parra Sanchez, Cecile A. C. M. van Els, Jelle De Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horvath, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adaja Elisabeth Baars, Dirkjan Hijnen, Corine R. G. Schreurs, W. Ludo Van der Pol, H. Stephan Goedee, Sofie Keijzer, Jim Keijser, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, S. Marieke van Ham, Taco W. Kuijpers, Theo Rispens, Filip Eftimov
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Koos P. J. van Dam, Luuk Wieske, Eileen W. Stalman, Laura Y. L. Kummer, Jesse Roosen, Zoe L. E. van Kempen, Joep Killestein, Adriaan G. Volkers, Laura Boekel, Gerrit J. Wolbink, Anneke J. van der Kooi, Joost Raaphorst, Mark Lowenberg, R. Bart Takkenberg, Geert R. A. M. D'Haens, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cecile A. C. M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horvath, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renee C. F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adaja E. Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim B. D. Keijser, Olvi Cristianawati, Theo Rispens, Anja ten Brinke, Niels J. M. Verstegen, S. Marieke van Ham, Sander W. Tas, Taco W. Kuijpers, Filip Eftimov
Summary: This study aimed to assess changes in disease activity after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases (IMIDs) and identify risk factors for increased disease activity. The results showed that a minority of patients reported increased disease activity after vaccination, but most cases were mild. Disease-related factors were found to have a major impact on the increased disease activity, rather than the vaccinations themselves.
JOURNAL OF AUTOIMMUNITY
(2023)
Article
Rheumatology
Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan H. Schirmer, Alvise Berti, Daniel Blockmans, Maria C. Cid, Julia U. Holle, Nicole Hollinger, Omer Karadag, Andreas Kronbichler, Mark A. Little, Raashid A. Luqmani, Alfred Mahr, Peter A. Merkel, Aladdin J. Mohammad, Sara Monti, Chetan B. Mukhtyar, Jacek Musial, Fiona Price-Kuehne, Marten Segelmark, Y. K. Onno Teng, Benjamin Terrier, Gunnar Tomasson, Augusto Vaglio, Dimitrios Vassilopoulos, Peter Verhoeven, David Jayne
Summary: Since the publication of the EULAR recommendations for the management of AAV in 2016, several clinical trials have been conducted that have the potential to change clinical care. A systematic literature review and expert opinions were used to modify existing recommendations and create new ones. The recommendations provide updated guidance on AAV management.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Chi Chiu Mok, Y. K. Onno Teng, Ramesh Saxena, Yoshiya Tanaka
Summary: In systemic lupus erythematosus, kidney involvement known as lupus nephritis is a serious condition with limited treatment options. This review analyzes current management guidelines, discusses emerging therapies, and explores the potential for precision medicine in treating lupus nephritis. Despite advancements, the prognosis for lupus nephritis has not significantly improved, and there are variations in treatment recommendations due to inter-ethnic differences and lack of evidence. New treatments and investigational drugs, such as calcineurin inhibitors and biologic agents, offer hope for improved outcomes. Molecular profiling and urine proteomic panels may help personalize treatment in the future.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Mathematics, Applied
Yuankai Teng, Zhu Wang, Lili Ju, Anthony Gruber, Guannan Zhang
Summary: Due to the challenge of dimensionality and limited training data, approximating high-dimensional functions is a difficult task. This paper introduces a new method called Dimension Reduction via Learning Level Sets (DRiLLS) for function approximation. The method uses a pseudoreversible neural network (PRNN) module to transform high-dimensional inputs to low-dimensional active variables, and a synthesized regression module to approximate function values in the low-dimensional space. Experimental results show that DRiLLS outperforms other methods, especially for target functions with critical points.
SIAM JOURNAL ON SCIENTIFIC COMPUTING
(2023)
Article
Urology & Nephrology
Jonathan Barratt, Brad Rovin, Muh Geot Wong, Charles E. Alpers, Stewart Bieler, Ping He, Jula Inrig, Radko Komers, Hiddo J. L. Heerspink, Alex Mercer, Irene L. Noronha, Jai Radhakrishnan, Michelle N. Rheault, William Rote, Howard Trachtman, Hernan Trimarch, Vlado Perkovic, PROTECT Investigators
Summary: The PROTECT trial is a multicenter, international study evaluating the efficacy and safety of sparsentan versus irbesartan in IgA nephropathy patients. Baseline characteristics of enrolled patients are described and compared to other relevant studies. The results will provide important characterization of the treatment effect in IgA nephropathy patients at high risk of kidney failure.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Urology & Nephrology
Dana Rizk, Brad H. Rovin, Hong Zhang, Naoki Kashihara, Bart Maes, Hernan Trimarchi, Vlado Perkovic, Matthias Meier, Dmitrij Kollins, Olympia Papachristofi, Alan Charney, Jonathan Barratt
Summary: APPLAUSE-IgAN is a Phase 3 study that aims to evaluate the benefits and safety of Iptacopan in reducing complement-mediated kidney damage and slowing down or preventing disease progression in IgA nephropathy.
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Urology & Nephrology
Sean J. Barbour, Fernando C. Fervenza, Dilshani Induruwage, Paul E. Brenchley, Brad Rovin, Michelle A. Hladunewich, Heather N. Reich, Richard Lafayette, Nabeel Aslam, Gerald B. Appel, Ladan Zand, Krzysztof Kiryluk, Lili Liu, Daniel C. Cattran
Summary: In patients with membranous nephropathy, combining anti-PLA2R antibody levels with albumin levels after 3 months of treatment is a better method to evaluate risk factors for treatment response probability, compared to using antibody levels alone or evaluating risk factors at baseline.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Rheumatology
Amit Saxena, Ellen M. Ginzler, Keisha Gibson, Bancha Satirapoj, Adolfina Elizabeth Zuta Santillan, Olena Levchenko, Sandra Navarra, Tatsuya Atsumi, Shinsuke Yasuda, Nilmo Noel Chavez-Perez, Cristina Arriens, Samir V. Parikh, Dawn J. Caster, Vanessa Birardi, Simrat Randhawa, Laura Lisk, Robert B. Huizinga, Y. K. Onno Teng
Summary: This study evaluated the long-term safety and efficacy of voclosporin in patients with lupus nephritis. The results showed that voclosporin treatment was well tolerated and led to improved renal response and reduced proteinuria over a three-year period.
ARTHRITIS & RHEUMATOLOGY
(2023)
Letter
Urology & Nephrology
Jolijn R. van Leeuwen, Sophia Hafemann, Paul van der Boog, Diane van der Woude, Ton Rabelink, Y. K. Onno Teng
CLINICAL KIDNEY JOURNAL
(2023)
Letter
Urology & Nephrology
Jolijn R. van Leeuwen, Ton J. Rabelink, Y. K. Onno Teng
KIDNEY INTERNATIONAL REPORTS
(2023)
Article
Medicine, Research & Experimental
Jolijn R. van Leeuwen, Tamara Popov, Achim Obergfell, Ton J. Rabelink, Y. K. Onno Teng
BIOLOGICS-TARGETS & THERAPY
(2023)
Article
Rheumatology
Brad H. Rovin, Richard A. Furie, Jorge A. Ross Terres, Sophia Giang, Thomas Schindler, Armando Turchetta, Jay P. Garg, William F. Pendergraft, Ana Malvar
Summary: Post hoc analyses of the NOBILITY trial showed that adding obinutuzumab to standard-of-care therapy for lupus nephritis resulted in better kidney function preservation and decreased risk of LN flares. More patients in the obinutuzumab group achieved complete renal response while using lower doses of glucocorticoids.
ARTHRITIS & RHEUMATOLOGY
(2023)